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REVIEW
Role of tiotropium in the treatment of COPD
Abstract: Tiotropium is a potent, long-acting, selective anticholinergic bronchodilator. Treat-
ment with tiotropium produces sustained improvements in lung function, particularly FEV1 
(peak, trough, average, and area under the curve) compared with either placebo or ipratropium 
in patients with moderate to severe COPD. Preliminary evidence suggests that treatment with 
tiotropium may slow the rate of decline in FEV1, but this ﬁ  nding awaits conﬁ  rmation. Tiotropium 
reduces lung hyperinﬂ  ation, with associated improvements in exercise capacity. Tiotropium, 
compared with either placebo or ipratropium, improves a variety of patient-centered outcomes, 
including subjective dyspnea ratings and HRQL scores. Tiotropium reduces the frequency of 
COPD exacerbations and of hospitalizations due to exacerbations, but has not been shown to 
reduce all-cause mortality. Compared with the long-acting bronchodilators, tiotropium provides 
incrementally better bronchodilation, but it is not clearly superior in terms of patient-centered 
outcomes. Tiotropium has a good safety proﬁ  le; however patients with severe cardiac disease, 
bladder outlet obstruction, or narrow angle glaucoma were excluded from all studies. Medico 
economic analyses suggest that treatment with tiotropium may also be cost-effective, primarily 
by reducing costs associated with hospitalizations.
Keywords: tiotropium, anticholinergic bronchodilator, chronic obstructive pulmonary 
disease
Introduction
It is estimated that COPD afﬂ  icts from 4% to 10% of adults and is the fourth leading 
cause of death worldwide (Sullivan et al 2000; World Health Organization 2000; 
Michaud et al 2001; Halbert et al 2003). The true global burden of COPD may be 
even greater as the condition is often under-diagnosed (Halbert et al 2003). Cigarette 
smoking is the primary cause of COPD, but environmental and genetic factors also 
contribute to the disease burden. The primary objective of COPD management is 
disease prevention through promoting smoking cessation and improving air quality. 
Other important goals of COPD management include efforts to slow progression of 
the disease, improve symptoms and overall health status, treat and prevent exacerba-
tions, and reduce mortality.
Inhaled bronchodilators play an important role for improving chronic symptoms and 
management of exacerbations in COPD, but they have not been shown to reduce mortal-
ity or slow the accelerated decline in lung function over time that typiﬁ  es this disease. 
The two major classes of inhaled bronchodilators commonly used for COPD are beta 
adrenergic agonists and anticholinergics. In recent years longer-acting bronchodilators 
of both drug classes have been widely introduced into clinical practice, either comple-
menting or replacing shorter-acting drugs. This article focuses on tiotropium (Spiriva®, 
Boehringer Ingelheim), a newly developed, long-acting, potent anticholinergic agent that 
was approved for use in Europe in 2002 and in the United States and Canada in 2004. We 
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will review what has been learned about the clinical beneﬁ  ts 
and safety of this drug, relying primarily on results from peer 
reviewed multi-dose, randomized, controlled trials. 
Mechanism of action
Atropine, as well as the short-acting inhaled bronchodila-
tor ipratropium, and the long-acting inhaled bronchodilator 
tiotropium, are muscarinic receptor antagonists. Unlike at-
ropine, tiotropium and ipratropium (Atrovent®, Boehringer 
Ingelheim) are quaternary ammonium cation compounds that 
are poorly absorbed across cell membranes, thus limiting 
their effects mainly to the airways after inhalation. Three 
types of muscarinic receptors have been identiﬁ  ed in human 
airways. Two of these receptors, M1 located in parasympa-
thetic ganglia, and M3 located on airway smooth muscle, me-
diate bronchoconstriction via the discharge of acetylcholine 
from vagal nerve endings (Belmonte 2005). M2 receptors 
are located on postganglionic cholinergic nerve endings 
and on smooth muscle and provide negative feedback so as 
to counteract smooth muscle contraction. Thus, antagonism 
of the M1 and M3 receptors reduce smooth muscle tone and 
cause beneﬁ  cial bronchodilation while inhibition of the M2 
receptor has the opposite effect. Ipratropium and atropine 
nonselectively block all three receptors, but tiotropium is 
more selective for the M1 and M3 receptors, from which it 
dissociates much more slowly (Barnes 2000). Consequently, 
tiotropium is a somewhat more potent bronchodilator than 
is ipratropium, and has a much longer duration of action. A 
single dose of inhaled tiotropium produces bronchodilation 
that is sustained for 24 hours or more (Barnes 2000).
Cholinergic-mediated pathways also modulate mucus 
production, vascular tone, and possibly a variety of immune 
pathways in the airways, raising the question as to whether 
any of the clinical beneﬁ  ts of anticholinergic therapy in 
COPD might be mediated via mechanisms other than bron-
chodilation (Koyama et al 1992; Nomura et al 2003; Bel-
monte 2005). The evidence for this is inconclusive. Excess 
mucus production is thought to be clinically important in 
COPD. However, efforts to show that inhaled anticholin-
ergics reduce the volume of sputum production in patients 
with obstructive lung disease have yielded mixed results 
(Lopez-Vidriero et al 1975; Tamaoki et al 1994).
Characteristics of study populations
All tiotropium trials conducted to date enrolled relatively 
homogeneous populations of COPD patients (Table 1). Most 
patients had moderate to severe disease by spirometric criteria 
(forced expiratory volume in one second/forced vital capacity 
[FEV1/FVC] < 0.70 and FEV1 < 65% of predicted) (National 
Heart, Lung and Blood Institute 2005). Patients with predomi-
nant asthma were excluded by clinical criteria. The majority of 
participants were men, and the average age of patients in most 
trials was typically in a range of 60–70 years. All trials banned 
concomitant use of ipratropium, and most prohibited the use 
of long-acting beta agonists, but inhaled corticosteroids and 
unlimited albuterol rescue therapy were generally permitted. 
Most trials also excluded patients with unstable heart disease, 
severe or inadequately treated urinary outﬂ  ow obstruction, 
narrow angle glaucoma, or moderate to severe azotemia.
Delivery of tiotropium in all studies was by inhalation 
via a single-dose dry powder delivery device (Handihaler®, 
Boehringer Ingelheim) (Chodosh et al 2001). The dose of tiotro-
pium was 18 μg/ day, as dose-ranging studies indicated that 
higher doses increase the incidence of adverse effects without 
providing signiﬁ  cant additional improvement in pulmonary 
function (Littner et al 2000). Tiotropium was usually given in 
the morning, although the time of administration has little effect 
on lung function over a 24-hour period (Calverley et al 2003).
Effects on lung function and exercise
Spirometry
Treatment-related bronchodilator effects, as assessed by spi-
rometry, were evaluated in all tiotropium trials. Spirometry 
is a useful surrogate for clinical outcomes because airﬂ  ow 
limitation is a deﬁ  ning feature of COPD and because spiro-
metric variables such as the FEV1 correlate with the severity 
of respiratory symptoms, with exercise capacity, and with 
mortality, albeit in an imperfect fashion (Anthonisen et al 
1986). The FEV1 is easily measured, and because it is more 
reproducible than most other efﬁ  cacy outcomes in COPD, 
statistically signiﬁ  cant changes can be detected with rela-
tively modest sample sizes. Trough FEV1, measured in the 
morning 23–24 hours after the last dose of study drug, was 
the primary outcome in a number of tiotropium studies. Other 
spirometric assessments included FVC, peak and area under 
the curve for both FEV1 and FVC, and inspiratory capacity 
(IC). The direction and relative magnitude of the changes 
seen with these measurements were generally similar to those 
observed with trough FEV1.
Several short-term (4–12 weeks) studies demonstrated 
that tiotropium increases mean peak FEV1 by between 210 
mL and 265 mL and mean trough FEV1 by between 120 mL 
and 184 mL (Celli et al 2003; O’Donnell et al 2004; Covelli 
et al 2005; Verkindre et al 2006). In a larger 12-week study, International Journal of COPD 2007:2(2) 97
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Beeh and associates showed that tiotropium increased mean 
trough FEV1 by an average of 79 mL, compared with placebo 
(Beeh et al 2006). They found larger improvements in aver-
age trough FEV1 (113 mL) in the subgroup of patients with 
milder COPD (FEV1 50%–70% predicted) compared with the 
group as a whole. In one trial, mean steady state trough FEV1 
occurred within 48 hours of treatment initiation, but mean 
FVC (trough and peak) continued to increase over the ﬁ  rst 
week of continuous treatment (van Noord et al 2002).
Longer-term studies demonstrated similar sustained 
improvements in lung function with tiotropium. At the end 
of one 13-week study in patients with severe COPD (mean 
baseline FEV1 38% predicted), treatment with tiotropium 
increased peak FEV1 by an average of 220 mL and trough 
FEV1 by an average of 150 mL compared with placebo 
(Casaburi et al 2000). In a 1-year study of 921 patients with 
severe COPD (mean baseline FEV1 38%–39% predicted), 
treatment with tiotropium, compared with placebo, improved 
mean trough FEV1 by between 120 and 150 mL on the various 
assessment days (Casaburi et al 2002). Similar results were 
reported in other 6-month and 12-month studies (Brusasco 
et al 2003; Niewoehner et al 2005). The MISTRAL study, 
performed in patients with somewhat milder COPD (mean 
FEV1 48% predicted), showed similar effects from tiotropium 
on both peak and trough FEV1 (Dusser et al 2006). Rodrigo 
and associates calculated that tiotropium, compared with 
placebo, conferred weighted mean improvements of 120 mL 
in the trough FEV1 and 210 mL in the peak FEV1 among 4214 
patients entered in eight trials (Rodrigo et al 2006). 
Overall, the correlation of FEV1 changes with clinically 
relevant outcomes, such as dyspnea and health-related qual-
ity of life (HRQL), is relatively weak in COPD patients and 
no general consensus exists as to what constitutes a clinically 
meaningful improvement. Anchoring of FEV1 changes to clini-
cal outcomes, such as dyspnea and exacerbation, suggests that 
increases on the order of 100 mL are clinically noticeable in 
certain settings (Redelmeier et al 1996; Niewoehner et al 2000; 
Donohue 2005). Thus, it is expected that the bronchodilator 
effects with tiotropium should be sufﬁ  ciently large to provide 
some meaningful impact on clinical outcomes.
Acute bronchodilator responses as 
predictors of long-term tiotropium 
responses
Although asthma patients were excluded by clinical criteria 
in all of the tiotropium trials, none were excluded because the 
acute bronchodilator response exceeded some arbitrary upper 
Table 1 Characteristics of trials and their study populations
Tiotropium vs   N  Duration   Age (yr)a Gender    FEV1
a FEV1/FVCa 
Placebo    of trial    male/female  (% predicted)  (%)
Beeh 2006  1639  12 wk  62   1237/402  45   57 
Calverly 2003  121  6 wk  66  75/46  41  51
Celli 2003  81  4 wk  64  50/31  38  43
Casaburi 2000  470  13 wk  65   307/163  39   46 
Casaburi 2002  921  12 mo  65  599/322  39  46
Covelli 2005  196  12 wk  65  114/82  39  NA
Dusser 2006  1010  12 mo  65  889/121  48  54
Littner 2000  169  4 wk  66  96/73  42  NA
Maltais 2005  261  6 wk  63  189/72  43  44
McNicholas 2004  95  4 wk  66  66/29  32  45
Niewoehner 2005  1829  6 mo  68  1802/27  36  48
O’Donnell 2004  187  6 wk  60  138/49  42  45
Verkindre 2006  100  12 wk  60  94/6  35  40
Tiotropium vs Ipratropium          
Van Noord 2000  288  3 mo  64  238/47b 41  45
Vincken 2002  535  12 mo  64  453/82  41  46
Tiotropium vs LABA         
Briggs 2003  653  6 mo  64  434/397  38  43
Brusasco 2003  1207  6 mo  64  920/287  38  43
van Noord 2005  71  6 wk  65  56/15  37  38
van Noord 2006  95  2 wk  64  72/23  38  41
aData are presented as means
b[sic] M/F numbers do not add up to total subjects in original report
Abbreviations: LABA, long-acting beta agonists.International Journal of COPD 2007:2(2) 98
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limit. Consequently, individual bronchodilator responses to 
a short-acting bronchodilator varied over a fairly wide range 
in those studies where that information is provided (Cazzola 
et al 2004a, b; Beeh et al 2006; van Noord et al 2006). None of 
the aforementioned studies reported whether initial responses 
to short-acting bronchodilators predicted long-term broncho-
dilator responses to tiotropium. In a secondary analysis of 
two 1-year trials, patients who had larger responses (12% 
increase and 200 mL in FEV1) to tiotropium on study 
day 1 were compared with patients with poorer responses 
to tiotropium (Tashkin et al 2003). Responsive patients, 
compared with less responsiveness patients, exhibited greater 
improvement in mean trough FEV1 at the end of the 1-year 
follow-up (212 ± 17 mL vs 94 ± 17 mL, respectively), but dif-
ferences in various clinical outcomes tended to be small and 
mostly statistically insigniﬁ  cant. Neither the initial response 
to a short-acting bronchodilator nor the initial response to 
tiotropium has been shown to provide useful information 
about long-term clinical outcomes with tiotropium. This is 
consistent with other evidence demonstrating the futility of 
using acute bronchodilator responses as a guide to therapy 
in COPD (Calverley et al 2003).
Disease modiﬁ  cation – FEV1 decline 
over time
Accelerated age-related decreases in the FEV1 typify the 
natural history of COPD. Though the FEV1 is a surrogate out-
come, it is widely accepted that slowing the decline in FEV1 
over time can be viewed as “disease modifying”, as there 
is the expectation of eventual reductions in morbidity and 
mortality. To date, smoking cessation is the only intervention 
that is known to slow the annual rate of decline in FEV1 in 
patients with COPD (Anthonisen et al 2002a). Pharmacologic 
interventions have been mostly unsuccessful. Several large 
randomized trials failed to show a statistically signiﬁ  cant 
effect of high dose inhaled corticosteroids on FEV1 decline 
over 3 years in patients with mild to moderate COPD, though 
summary estimates do not exclude a small effect (Highland 
et al 2003; Sutherland et al 2003). Similarly, the Lung Health 
Study found that regular treatment with ipratropium over a 
5-year period had no effect on the rate of decline in FEV1 in 
patients with mild COPD (Anthonisen et al 1994).
Preliminary evidence suggests that treatment with 
tiotropium might alter the progression of COPD. A post-hoc 
analysis of data from a previously published study (Casaburi 
et al 2002) found that treatment with tiotropium between 
study days 8 and 344 statistically signiﬁ  cantly reduced the 
mean rate of decline in trough FEV1 by 46 mL/year compared 
with placebo (Anzueto et al 2005). In a systematic review, 
Barr and colleagues conﬁ  rmed that result and also reported 
a similar effect from tiotropium when it was compared with 
ipratropium (Barr et al 2006a; Vincken et al 2002). A mean 
effect size of 46 mL/year is substantially larger than that 
reported in the ICS trials (5–8 mL/year) and would be viewed 
Table 2 Effect of tiotropium on spirometry
Tiotropium vs Placebo   FEV1 trough (mL)   FEV1 peak (mL)   FVC trough (mL)  FVC peak (mL) 
Beeh 2006   79  128  116  176
Calverly 2003  210  -  320  -
Celli 2003   160  220  330  480
Casaburi 2000   150  220  280  410
Casaburi 2002  120–150a 190–220a 260–290a 420–510a
Covelli 2005  184  265  213  388
Dusser 2006  120  -  170  -
Littner 2000  150  -  370  -
Maltais 2005  150  230  300  410
Niewoehner 2005   100  170  -  -
O’Donnell 2004  120  220  250  430
Verkindre 2006   110  210  80  -
Tiotropium vs Ipratropium      
Van Noord 2000   130  50  210  60
Vincken 2002  150  -  210  -
Tiotropium vs LABA      
Briggs 2003  18  46  120  64
Brusasco 2003  30  -  -  -
van Noord 2005  41  –3  74  –7
Notes: Data are presented as mean change from baseline.
aRange of change on different study days.
Abbreviations: LABA, long-acting beta agonists.International Journal of COPD 2007:2(2) 99
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as clinically meaningful, if conﬁ  rmed. These preliminary 
results formed the basis of the Understanding Potential Long-
term Impacts on Function with Tiotropium (UPLIFT) trial. 
The study has completed enrollment of 6000 patients with 
COPD and the primary objective is to determine whether 
tiotropium slows the decline in lung function (as measured 
by FEV1) over a 4-year period (Boehringer Ingelheim 2004). 
Results of the study are expected in 2008.
Dynamic hyperinﬂ  ation and exercise 
performance
Along with airﬂ  ow limitation, hyperinﬂ  ation is thought to play 
an important role in the genesis of exertional dyspnea, the symp-
tom that is so characteristic of more advanced COPD (Calverley 
et al 2006). In contrast to normal subjects, end-expiratory lung 
volume (EELV) increases during exercise in patients with 
severe COPD. Hyperinﬂ  ation can be assessed indirectly without 
resorting to plethysmography by measuring the reduction in IC 
(O’Donnell et al 1998). Hyperinﬂ  ation is essential for main-
taining the higher expiratory ﬂ  ow and minute ventilation rates 
that allow the COPD patient to meet the increased metabolic 
demands of exercise (Calverley et al 2006). However, dynamic 
lung hyperinﬂ  ation also carries a penalty because the respiratory 
system becomes progressively less compliant at larger lung 
volumes. It is thought that the resultant increase in the elastic 
component of respiratory muscle work has an important bearing 
on the sensation of breathlessness. 
O’Donnell et al (2004) compared tiotropium with placebo 
for 6 weeks and found that tiotropium increased resting and 
end-exercise IC and VC, decreased resting residual volume 
and functional residual volume, and improved mean exercise 
endurance time by an average of 105 sec (21%). In a 4-week 
study Celli et al (2003) showed that treatment with tiotro-
pium, compared with placebo, improved resting trough IC 
(by an average of 220 mL), and reduced trough thoracic gas 
volume (by an average of 540 mL). Similar effects on lung 
hyperinﬂ  ation and exercise have been reported in other trials 
(Maltais et al 2005; Beeh et al 2006; Verkindre et al 2006). 
Studies of dynamic hyperinﬂ  ation during exercise pro-
vide interesting new insights into the mechanism of dyspnea 
relief from bronchodilators in COPD patients. It has been 
suggested that bronchodilator-induced increases in IC and 
EELV may be better predictors of improvement in exertional 
dyspnea and exercise times than changes in FEV1, though this 
claim has not been fully substantiated (Belman et al 1996; 
O’Donnell et al 1998). IC measurements are substantially 
less reproducible than more conventional measurements, 
such as the FEV1 (ATS/ERS 2005), and their capability for 
distinguishing small bronchodilator effects is correspond-
ingly weaker. It also bears emphasizing that the capability 
for reducing dynamic hyperinﬂ  ation, though best studied 
with tiotropium, is most likely a generic effect common to 
all bronchodilators (Belman et al 1996).
Tiotropium may also provide a useful adjunct to 
pulmonary rehabilitation. Casaburi et al (2005) demonstrated 
that tiotropium ampliﬁ  ed the beneﬁ  ts of endurance training 
in patients with severe COPD (FEV1 35% predicted). Over 
an 8-week program, patients receiving tiotropium improved 
their mean constant work rate endurance time by 80% as 
compared with only 57% in patients receiving placebo. This 
difference was well maintained over a subsequent 12-week 
period when all patients continued study drug but received 
no further formal endurance training. 
Arterial blood gases and sleep-related 
oxygen desaturation
The effect of tiotropium on resting awake arterial blood gases 
has not been well studied, although tiotropium does improve 
sleep-related oxygen desaturation (SaO2) in patients with 
COPD. After 1 month of treatment with tiotropium, adminis-
tered once a day in the evening, mean SaO2 during REM was 
modestly (3.1%) but statistically greater than placebo, with a 
similar trend for patients who took tiotropium in the morning 
(McNicholas et al 2004). The improvement in SaO2 was most 
strongly correlated with increases in end-of-treatment FEV1. 
Tiotropium had no effect on the SaO2 while subjects were 
awake, the amount of time they spent in REM, or self-reports 
of sleep quality or daytime sleepiness. 
Table 3 Summary of tiotropium effects
Beneﬁ  ts
 •   Sustained effects for at least 24 hours from a single dose
 •   Improved lung function, exercise capacity, and health-related 
  quality-of-life 
 •   Reduced frequency of COPD exacerbation and related 
  hospitalizations
 •   Better bronchodilation compared with ipratropium or long-acting  
  beta  agonists
 •   Additive bronchodilation when combined with a long-acting beta  
  agonist
Adverse effects
 •  Dry  mouth
 •  Urinary  retention
 •   Safety in patients with severe cardiac disease, renal failure, 
    untreated bladder outlet obstruction or narrow angle glaucoma is  
  not  establishedInternational Journal of COPD 2007:2(2) 100
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Patient-centered outcomes
Direct measurement of patient-centered outcomes, such 
as health related quality of life, respiratory symptoms, ex-
acerbations, mortality, adverse drug events, and costs, are 
increasingly recognized as the most important components 
in COPD trials (Tashkin 2006). Tiotropium has been shown 
to improve many of these outcomes.
Health-related quality of life (HRQL) 
The St. Georges Respiratory Questionnaire (SGRQ) is the 
most widely used and arguably the best validated instrument 
for assessing health status in COPD patients. An improvement 
of at least 4 points in the SGRQ score is judged to be the clini-
cally meaningful difference (Jones et al 1997). In a summary 
analysis of 3 controlled trials, Barr et al (2006b) reported that 
tiotropium, compared with placebo, improved total SGRQ score 
by a weighted mean difference of –3.3 units (95% CI, –5.6 to 
–1.0). While the mean change fell short of the 4-unit change that 
is considered clinically noticeable, treatment with tiotropium, 
compared with placebo, did signiﬁ  cantly increase the likelihood 
that an individual patient would achieve an improvement of 4 
units or more (odds ratio, 1.9; 95% CI, 1.4–2.7).
Dyspnea
Dyspnea plays a central role in the disability of patients 
with advanced COPD (Ries 2006). Dyspnea evaluation is a 
component of the SGRQ, but the Transitional Dyspnea Index 
(TDI) provides a more speciﬁ  c assessment of functional 
impairment due to breathlessness (Mahler et al 1984). The 
clinically meaningful difference for the TDI score has been 
reported to be a 1 unit change (Witek et al 2003). Compared 
with placebo, tiotropium affected statistically signiﬁ  cant 
mean improvements of 1.1 units in a 6-month trial and 
0.8–1.1 units at various time points in a 1-year trial (Casaburi 
et al 2002; Brusasco et al 2003).
Exacerbations
Results from multiple trials consistently show that tiotropium, 
compared with placebo, reduces the frequency and severity 
of COPD exacerbations (Casaburi et al 2002; Brusasco et al 
2003; Niewoehner et al 2005; Verkindre et al 2005; Beeh 
et al 2006; Dusser et al 2006). Most trials were not clearly 
designed with exacerbation as the primary outcome and 
much of the information about exacerbations was collected 
through adverse event reporting. The single trial that was 
designed speciﬁ  cally to evaluate exacerbation frequency was 
also the largest of the trials and it fully conﬁ  rmed the results 
obtained in other studies (Niewoehner et al 2005). Though 
there was some variation from trial to trial, most used an 
“event-based” deﬁ  nition of exacerbation that required the 
occurrence of typical symptom complexes coupled with some 
form of medical intervention, such as antibiotic or systemic 
corticosteroid use.
Several meta-analyses summarized the results from 
available trials (Sin et al 2003; Wilt et al 2005; Barr et al 
2006a, b; Rodrigo et al 2006). A recent systematic review 
included 6 placebo-controlled trials of greater than 12 weeks 
duration and involving 6301 patients (Barr et al 2006b). The 
summary odds ratio of having one or more exacerbations 
for tiotropium, compared with placebo, was 0.74 (95% CI, 
0.66–0.83) (Figure 1). No subgroups have been clearly iden-
tiﬁ  ed to whom treatment is more effective or less effective. 
There is also solid evidence that tiotropium reduces the 
frequency of hospitalizations among those patients who suf-
fer a COPD exacerbation. Hospitalization is very important in 
human terms, because of its morbidity and increased risk of 
mortality, and in economic terms because of the inordinately 
high costs. In the United States, hospital admissions are the 
single largest source of medical expenditures for COPD, 
accounting for up to 70% of the total costs of medical care 
for this disease (Hilleman et al 2000).
Information about COPD hospitalization rates were pro-
vided in four large placebo-controlled trials (Casaburi et al 
2002; Brusasco et al 2003; Niewoehner et al 2005; Dusser 
et al 2006). All studies are consistent in showing fewer hos-
pitalizations among subjects who received tiotropium with 
the relative reduction in individual trials ranging between 
13% and 42%. Barr et al (2006b) calculated the summary 
odds ratio for tiotropium relative to placebo in these 4 trials 
as being 0.69 (95% CI, 0.55–0.87) (Figure 1).
Since most COPD exacerbations are thought to be 
caused by infections, the mechanism by which tiotropium 
reduces the frequency and severity of COPD exacerbations is 
uncertain. Improvements in lung function and dyspnea could 
reduce patients’ perception of the severity of exacerbations, 
thereby decreasing the likelihood that they would seek 
medical attention. That event would not be counted as an 
exacerbation, as exacerbation has been deﬁ  ned in most of the 
tiotropium trials. Other possible mechanisms might include 
more efﬁ  cient cough and clearance of respiratory secretions 
due to better bronchodilation, protection against lung injury 
due to hyperinﬂ  ation, or speciﬁ  c anticholinergic effects on 
mucus secretion or bronchial inﬂ  ammation (Niewoehner et al 
2005; Turino 2005).International Journal of COPD 2007:2(2) 101
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A
B
C
Study
or sub-category
01 vs placebo
01 vs placebo
02 vs ipratropium
02 vs ipratropium bromide
03 vs salmeterol
03 vs salmeterol
Vincken 2002
Briggs 2005
Brusasco 2003
Briggs 2005
Brusasco 2003
Beeh 2004
Brusasco 2003
Brusasco 2003
Casaburi 2002
Casaburi 2002
Dusser 2006
Dusser 2006
Dusser 2006
Niewoehner 2004
Niewoehner 2004
01 vs placebo
Brusasco 2003
Casaburi 2002
Casaburi 2005
Niewoehner 2004
Verkindre 2005
Subtotal (95% Cl)
Subtotal (95% Cl)
Subtotal (95% Cl)
Subtotal (95% Cl)
Subtotal (95% Cl)
Subtotal (95% Cl)
Total events: 1012 (Tiotropium), 998 (Control)
Total events: 134 (Tiotropium), 175 (Control)
Total events: 38 (Tiotropium), 39 (Control)
Total events: 26  (Tiotropium), 21 (Control)
Total events: 16 (Tiotropium), 29 (Control)
Test for heterogeneity: Chi2 = 2.60, df = 5 (P = 0.76), I2 = 0%
Test for heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79), I2 = 0%
Test for heterogeneity: Chi2 = 1.64, df = 3 (P = 0.65), I2 = 0%
Test for heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66), I2 = 0%
Test for heterogeneity: Chi2 = 3.38, df = 4 (P = 0.50), I2 = 0%
Test for heterogeneity: Chi2 = 2.17 df = 1 (P = 0.14), I2 = 54.0%
Test for  overall effect: Z = 5.24 (P < 0.00001)
Test for  overall effect: Z = 1.18 (P = 0.24)
Test for  overall effect: Z = 3.12 (P = 0.002)
Test for overall effect: Z = 1.69 (P = 0.009)
Test for overall effect: Z = 1.93 (P = 0.05)
Test for overall effect: Z = 0.41 (P = 0.68)
Test for overall effect: Z = 1.28 (P = 0.20)
COPD exacerbations
Tiotropium
n/N n/N
Control OR (fixed)
95% CI
OR (fixed)
95% CI
Study
or sub-category
Study
or sub-category
Tiotropium
n/N
n/N
n/N
Control
n/N
Control Tiotropium Control
OR (fixed)
95% CI
OR (fixed)
95% CI
OR (fixed)
95% CI
R (fixed)
95% CI
180/1236
129/402
198/550
250/500
255/914
308/510
296/915
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Mortality
Salpeter and associates reported that inhaled anticholinergics 
(tiotropium and ipratropium trials combined), compared with 
placebo, reduced the risk of respiratory deaths (RR 0.27, 
95% CI 0.09–0.81) based on a meta-analysis of 5 trials with 
7881 participants (Salpeter et al 2006). However, the total 
number of respiratory deaths were few and ascertainment of 
disease-speciﬁ  c mortality is fraught with uncertainties. In 6 
trials involving 4770 patients, Barr and colleagues found that 
treatment with tiotropium, compared with placebo, did not 
signiﬁ  cantly reduce all-cause mortality (OR, 0.91; 95% CI, 
0.58–1.42) (Barr et al 2006b) (Figure 1). Because of its large 
size and long duration, the UPLIFT study should provide 
more deﬁ  nitive information about the effect of tiotropium 
on mortality.
Comparisons with active controls
One randomized trial compared tiotropium to inhaled 
ipratropium (40 μg qid) as an active control over a 1-year 
period in 535 patients (Vincken et al 2002). Results were 
closely similar to those trials in which tiotropium was 
compared with placebo. At the end of 1 year, trough FEV1 
was significantly increased by a mean of 120 mL in the 
tiotropium arm, compared with ipratropium. Additionally, 
tiotropium, compared with ipratropium, improved the 
average TDI score by nearly 1 unit, improved average 
total SGRQ score by 3.3 units, and reduced the propor-
tion of patients who experienced one or more exacerba-
tions (35% vs 46%), all differences being statistically 
significant (p < 0.05). There was no significant effect 
on mortality (Figure 1). Dry mouth was the only adverse 
event that was significantly increased in the tiotropium 
arm (12% vs 6%).
Two trials, one of 12 weeks’ duration and involving 
653 patients and the other of 6 months’ duration and 
involving 807 patients, compared tiotropium with inhaled 
salmeterol (50 μg bid) (Brusasco et al 2003; Briggs et al 
2005). Summary analyses of these two trials indicate 
that tiotropium was superior to salmeterol in terms of 
trough FEV1 at the conclusion of the trials (weighted 
mean difference, 29 ml; 95% CI, 6–51 mL) (Barr et al 
2006b). Though trends favored tiotropium in certain other 
outcomes, SGRQ scores, TDI scores, exacerbation rates, 
and mortality did not differ statistically between the two 
treatment arms (Figure 1). As in other trials, there were 
more reports of dry mouth with tiotropium compared 
salmeterol.
Combination therapy with 
long-acting beta agonists
International guidelines for COPD treatment recommended 
long-acting bronchodilators, either a beta agonist or an an-
ticholinergic, for patients with moderately severe COPD or 
respiratory symptoms that persist despite the administration 
of short acting bronchodilators (Canada Thoracic Society 
2003; ATS/ERS 2004; National Clinical Guideline UK 
2004; National Heart, Lung and Blood Institute 2005). As 
with tiotropium, long-acting beta agonists increase the FEV1, 
improve HRQL and dyspnea scores, and reduce exacerbation 
rates (Wilt et al 2005). The guidelines state no preference of 
one class of long-acting bronchodilator over the other, nor do 
they recommend combination treatment with these agents. 
There is limited information about the clinical beneﬁ  ts 
of combining tiotropium with a long-acting beta agonist. 
Small, single-dose trials demonstrated additive FEV1 
improvements when tiotropium is combined with either 
salmeterol or formoterol (Cazzola et al 2004a, b). Van Noord 
et al (2005) showed in a 6-week study that, compared with 
baseline, average daytime FEV1 improvements over 12 hours 
with tiotropium alone, formoterol (12 μg) twice daily, and 
tiotropium plus once-daily formoterol were 127 mL, 86 mL, 
and 234 mL, respectively. Average 12 hour night-time FEV1 
improvements were 43 mL, 38 mL, and 86 mL, respectively. 
In another study of tiotropium alone or in combination with 
formoterol, the authors found that, compared with baseline, 
average FEV1 improvements over 24 hours with tiotropium 
alone, tiotropium plus once-daily formoterol, and tiotropium 
plus twice-daily formoterol were 80 mL, 162 mL, and 198 
mL, respectively (van Noord et al 2006). There was also a 
signiﬁ  cant reduction in albuterol rescue medication in the 
patients receiving both tiotropium and formoterol, but the 
trial was not powered to show differences for most relevant 
clinical outcomes. In contrast with the two previous trials, 
investigators in another study (van Noord et al 2006) found 
that, after 7 days of treatment, the difference in average 
FEV1 improvement 2 hours after a dose of formoterol was 
124 mL greater than with tiotropium; at 12 hours there was 
no signiﬁ  cant difference.
The Canadian Optimal Therapy of COPD trial is a 
3-arm study in 449 patients that compared tiotropium alone, 
tiotropium plus salmeterol, and tiotropium plus salmeterol 
plus ﬂ  uticasone for 52 weeks (Aaron et al 2007). Although 
there was no signiﬁ  cant difference in the primary outcome 
of the proportion of patients with exacerbations that re-
quired treatment with systemic steroids or antibiotics, other International Journal of COPD 2007:2(2) 103
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outcomes including lung function, disease-speciﬁ  c quality 
of life, hospitalizations for COPD, and all-cause hospitaliza-
tion favored treatment with tiotropium plus salmeterol plus 
ﬂ  uticasone compared with tiotropium plus placebo. There 
was no signiﬁ  cant differences in these outcomes, comparing 
tiotropium plus salmeterol with tiotropium alone.
Safety and adverse effects
Tiotropium has a quaternary ammonium structure so that it is 
poorly absorbed across cell membranes, thus limiting its activity 
to local bronchodilating effects and minimizing anticholinergic 
effects due to systemic absorption. Dry mouth is the most com-
monly reported adverse drug reaction from tiotropium (Kesten 
et al 2006). Approximately 4%–16% of patients experience 
this side-effect, although it tends to improve over time and it 
rarely (<1%) necessitates discontinuation of the drug (Tashkin 
et al 2003; Dusser et al 2006). In an analysis of pooled studies 
including 4435 tiotropium patients and 3384 placebo patients 
with 2159 and 1662 patient years of exposure, respectively, 
Kesten et al (2006) reported the relative risk for dry mouth in 
tiotropium patients was 3.60 (95% CI, 2.56–5.05).
Only miniscule amounts of tiotropium are absorbed 
systemically, but as a drug class, anticholinergics have a 
potential for causing adverse cardiac effects, particularly 
tachyarrhythmias. One published article reported a small 
excess number of tachyarrhythmias among patients with 
mild COPD who received ipratropium for several years 
(Anthonisen et al 2002). However, an excess number of 
serious cardiac side-effects in patients receiving tiotropium 
has not been reported in any of the published trials. Barr 
et al (2006b) found no signiﬁ  cant difference in the incidence 
of chest pain, myocardial infarction, congestive heart failure, 
arrhythmias, or atrial ﬁ  brillation with tiotropium compared 
with controls in their meta-analysis. Caution should be taken 
before applying these results to all patients with COPD, how-
ever, as many studies excluded patients with serious cardiac 
arrhythmias, recent myocardial infarctions, or hospitaliza-
tions for congestive heart failure.
Two studies provide more detailed information regarding 
potential adverse cardiac effects. One study found no 
evidence of cardiac toxicity after 6 weeks of tiotropium, as 
measured by 24-hour electrocardiographic (ECG) monitoring 
(Calverley et al 2003). A 12-week study found no signiﬁ  cant 
differences in heart rate, conduction abnormalities, rhythm, 
or QTc duration on 24-hour ECG monitoring over a 12-week 
period in patients receiving tiotropium, compared with pla-
cebo (Covelli et al 2005).
Adverse effects of tiotropium on urinary, renal, 
gastrointestinal, or ocular function appear to be infrequent. 
A small but statistically signiﬁ  cant increase in urinary tract 
infections with tiotropium was reported by Barr et al (2006b) 
in their meta-analysis, although there was no signiﬁ  cant 
increase in cases of urinary retention. In the analysis by 
Kesten et al (2006) the relative risk of urinary retention 
was 10.93 (95% CI, 1.26–94.88). Again, these results may 
not be generalizable to all patients with COPD, however, 
as patients with symptoms of moderately severe prostatic 
hypertrophy or bladder neck outlet obstruction were excluded 
from participation.
Patients with severe renal impairment were also excluded 
from most studies. An exception was one study in which 
tiotropium (4.8 μg) was administered intravenously over 15 
minutes to patients with levels of renal insufﬁ  ciency ranging 
from mild to severe (creatinine clearance of <30 mL/min) 
(Turck et al 2004). Blood levels of tiotropium, which is 
secreted mainly by the kidney in unchanged form, doubled 
in patients with severe renal impairment compared with those 
with normal renal function, but no adverse clinical effects 
were observed.
A substantial proportion of inhaled tiotropium is ingested 
and could in theory cause gastrointestinal dysmotility. In 
their meta-analysis, Barr et al (2006b) found no increase 
in reports of tiotropium-associated constipation. One case 
of postoperative paralytic ileus attributed to tiotropium has 
been reported (Praetorius et al 2005).
Due to its anticholinergic effects, tiotropium might also 
worsen the signs and symptoms of narrow-angle glaucoma, 
if drug were inadvertently deposited in the eye. One such 
case has been reported after self application directly in the 
eye, but exacerbation of glaucoma has not been reported 
when tiotropium is taken by inhalation as directed (Oksuz 
et al 2006). Nonetheless, tiotropium should be used with 
caution in patients with narrow angle glaucoma, since they 
were excluded from all trials.
Cost effectiveness
The cost effectiveness of tiotropium has been formally evalu-
ated based on data from studies performed in Europe and the 
United States. An economic analysis by Oostenbrink et al 
(2004) performed alongside a clinical trial in the Netherlands 
(Vincken et al 2002) showed that substituting tiotropium for 
ipratropium increased mean annual healthcare costs (including 
acquisition costs for tiotropium) by the equivalent of €180; the 
additional cost to prevent one COPD exacerbation was €667, International Journal of COPD 2007:2(2) 104
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and the cost to improve the SGRQ by at least 4 units was €1084. 
In a retrospective analysis of 2 studies performed in the United 
States (Casaburi et al 2002), Friedman et al (2004) found 
that treatment with tiotropium reduced average total annual 
healthcare costs by $US1043 (95% CI, –$US2136 to $US48), 
although this analysis excluded the costs of anticholinergic 
drug acquisition (Friedman et al 2004). The reduction in 
healthcare costs with tiotropium in this analysis was entirely 
due a reduction in the costs of hospitalizations. In a recent 
systematic review of the pharmacoeconomic evidence of 
maintenance treatment for COPD, D’Souza et al (2006) con-
cluded that treatment with tiotropium is cost-effective rela-
tive to ipratropium. These authors also found that treatment 
with inhaled corticosteroids is cost effective in patients with 
moderate-to-severe COPD, but data are lacking regarding the 
cost-effectiveness of long-acting beta agonists. 
Clinical implications
Tiotropium should be considered for maintenance therapy 
in patients with moderate to severe COPD. Improvements 
in pulmonary function with tiotropium are accompanied by 
improvements in dyspnea, exercise capacity, and HRQL, 
and a reduction in exacerbations. Although tiotropium has 
an excellent safety proﬁ  le in selected patients, the risks and 
beneﬁ  ts should be carefully weighed in patients with closed 
angle glaucoma, bladder outlet obstruction or severe cardiac 
disease. Limited data support the superiority of tiotropium 
compared with ipratropium; there is insufﬁ  cient clinical 
evidence to support the choice of tiotropium over long-acting 
beta agonists. Tiotropium may reduce the economic burden 
of COPD by reducing the frequency of COPD exacerbations 
and COPD-related hospitalizations.
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